Topic hub

Regulatory beat

The regulatory picture for peptides changed in 2023 when the FDA moved several compounds to Category 2 under the PCAC review process — effectively restricting compounding pharmacies from producing them. The July 2026 PCAC docket is the next inflection point. BPC-157, TB-500, and a handful of GHRPs are on the list. The outcome matters: category 1 means compounding continues, category 2 means the only legal path is a licensed drug. This hub tracks the regulatory timeline in real time, without the hype in either direction.

Join the waitlist

State of the evidence

The PCAC review (July 23–24, 2026) is the most significant regulatory event in the peptide space since 2023. The FDA's category 1 (clear clinical need, compound) vs category 2 (no demonstrated need) designation determines which peptides survive as compounded products. BPC-157, TB-500, and several GHRPs are on the docket. The DEA scheduling picture for peptide precursors adds a second layer of complexity. This section tracks both tracks in real time.

Signal snapshot: 2026-05-21

Peptide access by US state: why the regulatory patchwork right now is real

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

What is the PCAC? The advisory committee between peptides and FDA approval

The Pharmacy Compounding Advisory Committee is the FDA panel deciding which peptides US compounding pharmacies will be allowed to dispense by prescription. Two meetings, twelve peptides, and a vote that is not the same as a drug approval.

Sermorelin vs tesamorelin: two routes to the same receptor, two very different approval histories

WADA

Sermorelin and tesamorelin hit the same pituitary receptor and pull the same upstream lever on growth hormone. One had two FDA approvals and lost them for business reasons. The other still has one, for a population almost no buyer belongs to. Same mechanism, different paperwork.

AOD-9604: the weight-loss peptide that almost got approved

WADA

AOD-9604 was built on a clean mechanistic premise — the fat-burning piece of growth hormone, isolated from the rest. The mouse work was real. The human Phase II results disappointed. The molecule pivoted to joints, then to muscle preservation in the GLP-1 era. Here is the actual story.

Epithalon: Telomere, Anti-Aging Research, and the July 2026 PCAC Review

WADA

Science-journalism overview of Epithalon (Epitalon) — the tetrapeptide studied for telomerase activation and anti-aging effects, its preclinical and limited human evidence base, and its position on the PCAC July 2026 docket.

KPV: Anti-Inflammatory Peptide Research and the PCAC July 2026 Docket

Science-journalism overview of KPV — the alpha-MSH tripeptide fragment studied for gut inflammation and wound healing, its evidence base, and its position on the PCAC July 23–24 2026 review agenda.

PT-141 / Bremelanotide: FDA-Drug-Approved Sexual Health Peptide and Off-Label Use

Science-journalism overview of PT-141 (bremelanotide) — the melanocortin agonist with regulatory approval for hypoactive sexual desire disorder in women, its mechanism, clinical evidence, and the off-label interest driving compounding demand.

Semax: Neuroprotection and Cognitive Research on a Russian ACTH Analog

WADA

Science-journalism overview of Semax — the ACTH-derived heptapeptide studied for neuroprotection and cognitive enhancement, what preclinical and limited human data show, and its position on the PCAC July 2026 docket.

TB-500 / Thymosin Beta-4: Tissue Repair Research and Regulatory Overview

WADA

Science-journalism overview of TB-500 (Thymosin Beta-4) research — what animal and limited human data suggest about tissue repair, and where the compound stands under PCAC July 2026 review.

Tesamorelin: Drug-Approved GH Analog, Off-Label Use, and Compounding Restrictions

WADA

Science-journalism analysis of tesamorelin — the GHRH analog with a specific FDA drug approval for HIV-associated lipodystrophy, what off-label interest means, and why compounding restrictions apply.

Thymosin Alpha-1: Immune Modulation Research and Regulatory Overview

WADA

Science-journalism overview of Thymosin Alpha-1 — the thymic peptide with extensive clinical development history in immunology, its evidence base in infections and cancer, and why it occupies a distinct regulatory category in the United States.

BPC-157: what the evidence actually says (and what it doesn't)

WADA

An honest read on BPC-157 — what hundreds of animal studies actually show, what the human evidence really is (two small uncontrolled pilots), and where the compound sits ahead of the FDA's July 2026 compounding review.